Treatment Breakthrough for Sclerotic Interstitial Lung Disease

Scleroderma patients and patients with systemic sclerosis run a very high risk for Interstitial Lung Disease and it is the leading cause of death for these patients. The new approved drug can slow the rate of decline in pulmonary function. Click to learn more.